BrookeE.DanielMD

Oncology • Chattanooga, TN

Physician

Join to view full profile

Are you Dr. Daniel?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 78 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
605 Glenwood Dr
Suite 200
Chattanooga, TN 37404
Phone+1 423-698-1844

Fax+1 423-624-2226
Is this information wrong?

Summary

Dr. Brooke Daniel, MD is an oncologist in Chattanooga, Tennessee. She is currently licensed to practice medicine in Tennessee, Florida, and Georgia. She is affiliated with CHI Memorial and Parkridge Medical Center.

Education & Training

Duke University HospitalFellowship, Hematology and Medical Oncology, 2002 - 2005
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1998 - 2001
University of Tennessee Health Science Center College of MedicineClass of 1998

Certifications & Licensure

FL State Medical License 2020 - Present
GA State Medical License 2005 - 2025
TN State Medical License 2005 - 2025
VA State Medical License 1998 - 2006
NC State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012

Clinical Trials

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
Completed
Phase 2
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
Completed
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Advancing the Care of Women With HER2-Positive Metastatic Breast Cancer.
Marcie Beasley, Brooke Daniel> ;Journal of the Advanced Practitioner in Oncology. 2023 Apr 1
27 citations
Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Ran...
Denise A. Yardley, James Reeves, E. Claire Dees, Cynthia R. C. Osborne, Devchand Paul, Foluso O. Ademuyiwa, Hatem Soliman, Troy Guthrie, Jay Andersen, Lea Krekow, Jana...> ;Clinical Breast Cancer. 2016 Dec 1
27 citations
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial
Denise A. Yardley, Patrick J. Ward, Brooke R. Daniel, Janice F. Eakle, Ruth E. Lamar, Cassie M. Lane, John D. Hainsworth> ;Clinical Breast Cancer. 2016 Oct 1
5 citations
Use of a multiplexed immunoassay (PRO Onc assay) to detect HER2 abnormalities in circulating tumor cells of women with HER2-negative metastatic breast cancer: lack of ...
John D. Hainsworth, Patrick B. Murphy, Jose R. Alemar, Brooke R. Daniel, Robyn R. Young, Denise A. Yardley> ;Breast Cancer Research and Treatment. 2016 Sep 8
3 citations
Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute
Denise A. Yardley, John D. Zubkus, Janice F. Eakle, Rebecca Bechhold, L Finney, Davey B. Daniel, Brooke R. Daniel, John D. Hainsworth> ;Clinical Breast Cancer. 2015 Aug 1
Join now to see all

Press Mentions

OneOncology Names Dr. Davey Daniel as Chief Medical OfficerFebruary 7th, 2022

Hospital Affiliations

CHI MemorialChattanooga, Tennessee
Parkridge Medical CenterChattanooga, Tennessee